Cognitive Impairment - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 129 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Cognitive Impairment - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Cognitive Impairment - Pipeline Review, H2 2014', provides an overview of the Cognitive Impairment's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Cognitive Impairment and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cognitive Impairment pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cognitive Impairment pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Cognitive Impairment Overview 8
Therapeutics Development 9
Pipeline Products for Cognitive Impairment - Overview 9
Pipeline Products for Cognitive Impairment - Comparative Analysis 10
Cognitive Impairment - Therapeutics under Development by Companies 11
Cognitive Impairment - Therapeutics under Investigation by Universities/Institutes 14
Cognitive Impairment - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Cognitive Impairment - Products under Development by Companies 18
Cognitive Impairment - Products under Investigation by Universities/Institutes 21
Cognitive Impairment - Companies Involved in Therapeutics Development 22
Bristol-Myers Squibb Company 22
F. Hoffmann-La Roche Ltd. 23
AstraZeneca PLC 24
Merck & Co., Inc. 25
Panacea Pharmaceuticals, Inc. 26
Pfizer Inc. 27
Teva Pharmaceutical Industries Limited 28
Shire Plc 29
Evotec AG 30
Suven Life Sciences Ltd. 31
AGY Therapeutics, Inc. 32
Cardax Pharmaceuticals, Inc. 33
Siena Biotech S.p.A. 34
Virogenomics, Inc. 35
Dart NeuroScience LLC 36
Omeros Corporation 37
Intra-Cellular Therapies, Inc. 38
Heptares Therapeutics Ltd. 39
Pacific Northwest Biotechnology, LLC 40
Vicore Pharma AB 41
Pherin Pharmaceuticals, Inc. 42
AbbVie Inc. 43
Saniona AB 44
Cognitive Impairment - Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Target 46
Assessment by Mechanism of Action 49
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 56
idursulfase - Drug Profile 56
Small Molecule to Target Free Radicals for Central Nervous System, Ophthalmology and Ear Nose Throat Disorders - Drug Profile 57
irdabisant - Drug Profile 59
ABT-560 - Drug Profile 60
PF-04958242 - Drug Profile 61
HTL-9936 - Drug Profile 62
BMS-933043 - Drug Profile 63
PAN-811 - Drug Profile 64
CDX-085 - Drug Profile 66
ITI-214 - Drug Profile 68
PH-15 - Drug Profile 69
EVT-501 - Drug Profile 70
Small Molecule to Antagonize GPR12 for Obesity, Cognitive Impairments and Motor Disorders - Drug Profile 71
C-21 - Drug Profile 72
Small Molecule to Target GPR151 for CNS Diseases - Drug Profile 74
Small Molecule to Target MAS1 for Cognitive Impairments, Blood Pressure Abnormalities and Colon Cancer - Drug Profile 75
2-PMPA - Drug Profile 76
NS-9283 - Drug Profile 77
BNC-375 - Drug Profile 79
Small Molecule to Inhibit GlyT-1 for Cognitive Impairment - Drug Profile 80
Small Molecule 1 for Cognitive Impairment - Drug Profile 81
Small Molecule 9 for Cognitive Impairment - Drug Profile 82
E-1R - Drug Profile 83
RO-4938581 - Drug Profile 84
Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile 85
SEN-15924 - Drug Profile 86
Drug to Agonize Muscarinic M1/M4 Receptors for CNS Disorders - Drug Profile 87
SUVN-90121 - Drug Profile 88
SLV-330 - Drug Profile 89
VU-0092273 - Drug Profile 90
RTL-551 - Drug Profile 91
rhTFAM for Sepsis and Cognitive Disorders - Drug Profile 92
Small Molecules to Agonize nAChR for Alzheimer's Disease and Cognitive Impairment - Drug Profile 94
Small Molecule to Antagonize Histamine 3 Receptor for Cognition - Drug Profile 96
xamoterol fumarate - Drug Profile 97
Small Molecules to Agonize Beta-1 Adrenergic Receptor for Cognitive Impairment - Drug Profile 98
Small Molecules to Agonize 5-HT4 Receptors for Cognitive Impairment - Drug Profile 99
Small Molecules to Antagonize 5-HT6 Receptors for Cognitive Impairment - Drug Profile 100
Small Molecules to Inhibit AGY-111 for Cognition and Schizophrenia - Drug Profile 101
Small Molecules to Inhibit Tyrosine Phosphatase for Cognition and Schizophrenia - Drug Profile 102
Small Molecules to Inhibit Glyt-1 for Cognitive Impairment - Drug Profile 103
Small Molecule 4 for Cognitive Impairment - Drug Profile 104
Small Molecule 10 for Cognitive Impairment - Drug Profile 105
Small Molecules to Agonize GABAA Receptor for Cognitive Impairment - Drug Profile 106
Small Molecule 2 for Cognitive Impairment - Drug Profile 107
Small Molecule 3 for Cognitive Impairment - Drug Profile 108
Stem Cell Therapy for Cognitive Impairment - Drug Profile 109
Small Molecule 11 for Cognitive Impairment - Drug Profile 110
Small Molecule 12 for Cognitive Impairment - Drug Profile 111
Small Molecule 5 for Cognitive Impairment - Drug Profile 112
Small Molecule 6 for Cognitive Impairment - Drug Profile 113
Small Molecule 7 for Cognitive Impairment - Drug Profile 114
Small Molecule 8 for Cognitive Impairment - Drug Profile 115
Cognitive Impairment - Recent Pipeline Updates 116
Cognitive Impairment - Dormant Projects 119
Cognitive Impairment - Discontinued Products 120
Cognitive Impairment - Product Development Milestones 121
Featured News & Press Releases 121
Appendix 125
Methodology 125
Coverage 125
Secondary Research 125
Primary Research 125
Expert Panel Validation 125
Contact Us 126
Disclaimer 126

List of Tables
Number of Products under Development for Cognitive Impairment, H2 2014 12
Number of Products under Development for Cognitive Impairment - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 15
Number of Products under Development by Companies, H2 2014 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2014 18
Comparative Analysis by Clinical Stage Development, H2 2014 19
Comparative Analysis by Early Stage Development, H2 2014 20
Products under Development by Companies, H2 2014 21
Products under Development by Companies, H2 2014 (Contd..1) 22
Products under Development by Companies, H2 2014 (Contd..2) 23
Products under Investigation by Universities/Institutes, H2 2014 24
Cognitive Impairment - Pipeline by Bristol-Myers Squibb Company, H2 2014 25
Cognitive Impairment - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 26
Cognitive Impairment - Pipeline by AstraZeneca PLC, H2 2014 27
Cognitive Impairment - Pipeline by Merck & Co., Inc., H2 2014 28
Cognitive Impairment - Pipeline by Panacea Pharmaceuticals, Inc., H2 2014 29
Cognitive Impairment - Pipeline by Pfizer Inc., H2 2014 30
Cognitive Impairment - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 31
Cognitive Impairment - Pipeline by Shire Plc, H2 2014 32
Cognitive Impairment - Pipeline by Evotec AG, H2 2014 33
Cognitive Impairment - Pipeline by Suven Life Sciences Ltd., H2 2014 34
Cognitive Impairment - Pipeline by AGY Therapeutics, Inc., H2 2014 35
Cognitive Impairment - Pipeline by Cardax Pharmaceuticals, Inc., H2 2014 36
Cognitive Impairment - Pipeline by Siena Biotech S.p.A., H2 2014 37
Cognitive Impairment - Pipeline by Virogenomics, Inc., H2 2014 38
Cognitive Impairment - Pipeline by Dart NeuroScience LLC, H2 2014 39
Cognitive Impairment - Pipeline by Omeros Corporation, H2 2014 40
Cognitive Impairment - Pipeline by Intra-Cellular Therapies, Inc., H2 2014 41
Cognitive Impairment - Pipeline by Heptares Therapeutics Ltd., H2 2014 42
Cognitive Impairment - Pipeline by Pacific Northwest Biotechnology, LLC, H2 2014 43
Cognitive Impairment - Pipeline by Vicore Pharma AB, H2 2014 44
Cognitive Impairment - Pipeline by Pherin Pharmaceuticals, Inc., H2 2014 45
Cognitive Impairment - Pipeline by AbbVie Inc., H2 2014 46
Cognitive Impairment - Pipeline by Saniona AB, H2 2014 47
Assessment by Monotherapy Products, H2 2014 48
Number of Products by Stage and Target, H2 2014 51
Number of Products by Stage and Mechanism of Action, H2 2014 54
Number of Products by Stage and Route of Administration, H2 2014 56
Number of Products by Stage and Molecule Type, H2 2014 58
Cognitive Impairment Therapeutics - Recent Pipeline Updates, H2 2014 119
Cognitive Impairment - Dormant Projects, H2 2014 122
Cognitive Impairment - Discontinued Products, H2 2014 123